Abstract
We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae. We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-1 K. pneumoniae pneumonia. Results showed that rCST9/rCSTC treatment modulated endogenous serum biomarkers, cystatins 9 and C and amyloid A, associated with poor patient outcomes and provided prophylactic and long-term protection in a murine model of pneumonia.
| Original language | English (US) |
|---|---|
| Article number | e02519-18 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 63 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2019 |
Keywords
- Adoptive B-cell transfer
- Amyloid A
- Cystatin 9
- Cystatin C
- Immunomodulation
- Immunotherapy
- Inflammation
- Multidrug resistant
- NDM-1 Klebsiella pneumoniae
- Pneumonia
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS